The list is updated every six months to promote transparency and encourage competition in markets with limited alternatives. The FDA publishes a list of approved new drug application (NDA) products that lost patent protection or exclusivity without an approved abbreviated new drug application (ANDA). The booklet continues with an update on regulatory approaches to and the impact of legalization on the non-medical cannabis market in different countries, and a review of the enabling environment that provides broad access to the unsupervised, “quasi-therapeutic” and non-medical use of psychedelic substances. The chapter also assesses the extent to which drug production and trafficking are linked with other illicit economies that challenge the rule of law and fuel conflict. This is followed by a chapter examining the convergence of drug trafficking and other activities and how they affect natural ecosystems and communities in the Golden Triangle in South-East Asia. Shivani Zoting is a dedicated research analyst specializing in the healthcare industry.
The Unrelenting Pressure Of Healthcare Costs
By type, the prescription segment held the major share of the pharmaceutical market in 2023. Under typical market settings, rising healthcare expenses would result in higher generic medicine prices due to the growing demand for these medications. As consumers and payers look for methods to reduce healthcare expenses, the demand for generic medications is still rising globally. The United States was the largest national pharmaceutical market in 2024, making up around 53 percent of the total pharmaceutical prescription drug market worldwide. The region's well-established healthcare and pharmaceutical sectors support market growth.
Considering Psilocybin Legalization: Insights For New York And Other Jurisdictions
Navigating the world’s regulatory landscape is a complex and costly endeavor. This influx of suppliers inevitably triggers intense price wars, which, while beneficial for consumers and healthcare systems, can decimate profit margins for manufacturers. Conditions such as cancer, diabetes, cardiovascular disease, and respiratory illnesses are on the rise globally, necessitating long-term, often lifelong, medication regimens.2 For millions of patients, the affordability of these maintenance therapies is a primary concern.
US Prescription Drugs Market Segmentation Analysis
Similarly, governments of countries in Asia Pacific are focusing on pharmaceutical R&D activities. As per the European Federation of Pharmaceutical Industries and Associations (EFPIA), the research-based pharmaceutical industry in Europe invested ~US$ 44,266.18 million (€ 41,500 million) in R&D in 2021. These investments reflect the commitment of companies to creating life-enhancing innovations. Similarly, Johnson & Johnson invested US$ 14.7 billion in research and development in 2021, with an annual rise of 21% in its all-time-high investment recorded in 2020. In 2021, Pfizer Inc. invested US$ 13,829 million in research and development, recording an increase of US$ 4.4 billion from 2020 (US$ 9,393 million).
Technological Factors:
- With the growing burden of various life-threatening diseases, the demand for personalized medicine and digital health is rising, contributing to market expansion.
- In addition, the report offers insights into the market trends and highlights key industry developments.
- Germany Pharmaceutical market, 2018 – 2033 (USD Million)12.3.3.
- Hence, the simpler approval process of small molecule generics, increase in patent expiration of small molecules, and low cost of products drive the market.
- Moreover, the U.S. prescription drugs market size is projected to grow significantly, reaching an estimated value of USD 931.1 million by 2032, driven by rising approval of orphan drugs by regulatory agencies.
- Denmark Pharmaceutical market, 2018 – 2033 (USD Million)12.3.8.
The rising development of biologics and biosimilars create lucrative growth opportunities for the pharmaceutical market. The ongoing expiration of patents on branded drugs is shifting patients toward generic drugs. Government support and investments in research & development, wider use of biologics and biosimilars, and increased healthcare spending further support market growth. The economic impact of prescription drugs is substantial and often a topic of discussion in healthcare policy. Prescription drugs require a prescription from a healthcare professional, while over-the-counter drugs can be purchased directly from a pharmacy or store without a prescription. This is projected to positively impact the global market as these companies are expected to gain market share during the forecast period.
Drug Type
This market is expected to grow slowly during the COVID-19 pandemic. However, the market is projected to be stifled by government rules and medicine side effects. Rather than being connected with a specific manufacturer, generic medications are subject to government restrictions in various nations.
The oral segment accounted for the largest revenue share of 51.2% in 2024, due to ease of use and widespread application in chronic disease management. The immunology segment is expected to register the fastest CAGR of 8.1% from 2025 to 2032, owing to increasing cases of autoimmune disorders and advancements in biologics. Growing patient awareness, advanced regulatory frameworks, and robust distribution networks further reinforced North America’s leading revenue share.
Prescription Drugs Market Size
Novartis AG and Pfizer, Inc. are the leading players in the global market. In addition to the above-mentioned factors, the report includes numerous factors that have contributed to the growth of the market in the recent years. Also, the report offers insights into the market trends and highlights key industry developments. It focuses on key features such as the prevalence of key diseases – by key countries – pipeline analysis, key industry developments, new product approvals, and regulatory scenarios – by key regions. Despite that, a number of other prominent players, such as Roche, Johnson & Johnson, and Sanofi, also have strong market revenue shares in the global market. The rest of the world market comprises Latin America and the Middle East & Africa and is currently in a stage of growth.
After a 0.4% contraction in 2024, pharmaceuticals output and sales in the EU and the UK are anticipated to grow by 1.9% in 2025 and 0.4% in 2026. The National Pharmaceutical Policy helps cut costs and reduce reliance on Chinese API imports. India is set to be a major pharma manufacturer in the next decade, thanks to its growing population and increased healthcare spending. The company is the world's best-selling drug with sales that rose 18% to $29.5 billion in 2024 through Keytruda momentum. There is a high demand for mRNA vaccines, biologics, and biosimilars.
Regional Outlook For The Global Pharmaceutical Drugs Market
Because chronic diseases are so common, the government and many pharmaceutical companies are expanding their R&D spending to find novel compounds and improve existing technology. The rising prevalence of chronic diseases, the growing senior population, and rising healthcare costs are all factors contributing to this trend. COVID-19 has had a direct impact on supply and demand, causing supply chain disruption since many pharmaceuticals were unable to reach the market on time. In terms of dosage, strength, mode of administration, quality, performance, and application, these pharmaceuticals are less expensive and comparable to branded drugs. Equally, recently implemented strategies like the “safer supply” of drugs has had no impact on the development so far 64, 65. Although prescription opioid-involved deaths rates have remained relatively stable, it is important to remember what role prescription drug-control policies had in shaping the nature of today’s drug markets .
The pharmaceutical drugs market covered in this report is segmented – The pharmaceutical drugs market size is expected to see strong growth in the next few years. In Latin America, rising demand for generic drugs, propelled by affordability and efficiency, is a major trend in the drugs market.
India already supplies 20% of the world’s finished-dose generics and 60% of vaccines, while China is scaling bioreactor capacity for monoclonal antibody biosimilars. Asia is the fastest-growing territory with an 8.19% forecast CAGR. Supply-chain resilience has become a policy focus, and the European Commission evaluates incentives for onshoring critical generic production.
